CD20/CD19/CD22 Multi-targeted Chimeric Antigen Receptor T-cell (CAR-T) Therapy (Unicar-Therapy Bio-Medicine Technology)

N/A

Report date: 2026/05/07 20:00:36

Base Information

Drug NameCD20/CD19/CD22 Multi-targeted Chimeric Antigen Receptor T-cell (CAR-T) Therapy (Unicar-Therapy Bio-Medicine Technology)
Drug Alias NameTriple-targeted CAR-T Therapy (Unicar-Therapy Bio-Medicine Technology)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionAnti-CD19T lymphocyte replacementsB-lymphocyte antigen CD20 modulators +[4] 
TargetsB-lymphocyte antigen CD19B-lymphocyte antigen CD20CD22
Therapy Area/IndicationsLymphoma, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaDiscontinued
Originator CompaniesShanghai Unicar-Therapy Bio-Medicine Technology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesShanghai Unicar-Therapy Bio-Medicine Technology Co Ltd
Active IndicationsN/A
Inactive IndicationsLymphoma, B-Cell

Other Information

ATC CodeN/A
Related LinksN/A